CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 400 enrolled
Drug / intervention
Compound Edaravone Injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01929096
NCT01929096Phase 2Completed
CompareCT.gov

Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Multi-dose, Parallel, and Controlled Phase II Trial

Jiangsu Simcere Pharmaceutical Co., Ltd.·interventional·Posted Aug 27, 2013·Updated Jul 3, 2015

In Brief

A Phase 2 clinical trial evaluating Compound Edaravone Injection and Edaravone Injection for Acute Ischemic Stroke. Completed, enrolled 400 participants across 28 sites.

Detailed Summary

1. To investigate the efficacy and safety of multi-doses Compound Edaravone Injection versus Edaravone Injection for acute ischemic stroke patients; 2. To provide evidence for the design of Compound Edaravone Injection Phase III trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Ischemic Stroke
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 27, 2013
Enrollment StartAug 1, 2013
Primary CompletionDec 1, 2014
Study CompletionFeb 1, 2015
TodayJul 1, 2026
Enrollment to primary: 1.3 yearsPosted 12.8 years ago

Interventions

Compound Edaravone Injectiondrug

Edaravone Injectiondrug